newsfilter
← Latest News
GlobeNewswire·

Anavex Life Sciences Provides Comprehensive Regulatory Update

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease Additional data submitted to the U.S. FDA with the objective to discuss